THE USE OF BLOOD COAGULATION LABORATORY PARAMETERS FOR ASSESSMENT OF BLEEDING RISK DURING RADIOFREQUENCY ABLATION PROCEDURE IN ATRIAL FIBRILLATION PATIENTS RECEIVING DABIGATRAN ETEXILATE
https://doi.org/10.29001/2073-8552-2017-32-4-17-22
Abstract
The article presents the results of the analysis of hemostasis parameters in atrial fibrillation patients with and without anticoagulation therapy with dabigatran etexilate in the perioperative period of the arrhythmia ablation. We evaluated the capabilities of using the conventional indicators of the blood coagulation in atrial fibrillation patients receiving dabigatran etexilate to assess the possible risk of bleeding in the perioperative period of radiofrequency ablation.
About the Authors
S. Yu. Usenkov
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk
Russian Federation
Cand. Sci. (Med.), Surgeon, Heart Arrhythmias Department, Cardiology Research Institute
Russian Federation
Cand. Sci. (Med.), Surgeon, Heart Arrhythmias Department, Cardiology Research Institute
R. E. Batalov
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk
Russian Federation
Dr. Sci. (Med.), Senior Researcher, Heart Arrhythmias Department, Cardiology Research Institute
Russian Federation
Dr. Sci. (Med.), Senior Researcher, Heart Arrhythmias Department, Cardiology Research Institute
E. V. Borisova
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk
Russian Federation
Cand. Sci. (Med.), Researcher, Heart Arrhythmias Department, Cardiology Research Institute
Russian Federation
Cand. Sci. (Med.), Researcher, Heart Arrhythmias Department, Cardiology Research Institute
M. S. Khlynin
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk
Russian Federation
Cand. Sci. (Med.), Junior Researcher, Heart Arrhythmias Department, Cardiology Research Institute
Russian Federation
Cand. Sci. (Med.), Junior Researcher, Heart Arrhythmias Department, Cardiology Research Institute
E. A. Аrchakov
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk
Russian Federation
Postgraduate, Heart Arrhythmias Department, Cardiology Research Institute
Russian Federation
Postgraduate, Heart Arrhythmias Department, Cardiology Research Institute
S. V. Popov
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk
Russian Federation
Dr. Sci. (Med.), Professor, Member of the Russian Academy of Sciences, director of the Cardiology Research Institute
Russian Federation
Dr. Sci. (Med.), Professor, Member of the Russian Academy of Sciences, director of the Cardiology Research Institute
References
1. Баталов Р.Е., Антонченко И.В., Попов С.В. Антикоагулянтная терапия для фибрилляции предсердий / Российский медицинский журнал. 2017; 19(14): 905–909. [Batalov R.E., Antonchenko I.V., Popov S.V. Anticoagulation therapy for atrial fibrillation / Russian Medical Journal. 2011; 19(14): 905–909] (In Russ).
2. Баталов Р.Е., Попов С.В., Егай Ю.В. Лечение фибрилляции предсердий (обзор литературы) / Сибирский медицинский журнал. 2011; 26(4): 8–14. [Batalov R.E., Popov S.V., Egay Yu.V. Atrial fibrillation treatment (literature review) / Siberian Medical Journal. 2011; 26(4): 8–14] (In Russ).
3. Моисеев С.В. Когда и как применять дабигатран при фибрилляции предсердий / Рациональная фармакотерапия в кардиологии. 2012; 6(8): 819–824. [Moiseev S.V. How to use dabigatran in patients with atrial fibrillation / Rational Pharmacotherapy in Cardiology. 2012; 6(8): 819–824] (In Russ).
4. Хорев Н.Г., Момот А.П., Залозный Д.А. Новые оральные антикоагулянты (обзор литературы) / Фарматека. 2010; 18/19: 20–26. [Khorev N.G., Momot A.P., Zapozliy D.A. New oral anticoagulants (literature review) / Pharmateca. 2010; 18/19: 20–26] (In Russ).
5. Шубик Ю.В. Антитромботическая терапия при фибрилляции предсердий /Вестн. аритмологии. 2014; 75: 50–75. [Shubik Yu.V. Antithrombotic therapy in atrial fibrillation / Vestar. 2014; 75: 50–75] (In Russ).
6. Heeringa J., van der Kuip D., Hofman А. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study / Eur. Heart J. 2006; 27: 949–953.
7. Prystowsky E., Katz A. Atrial fibrillation in textbook of cardiovascular medicine. Philadelphia : Lippincott-Raven, 1998: 1661.
8. Patel M.R., Mahaffey K.W., Garg J. For the ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation / N. Engl. J. Med. 2011; 365: 883–891.
9. Wann L.S., Curtis A.B., Januaru C.T. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 Guideline) / Heart Rhythm. 2011; 8: 158– 176.
10. Wyse D. The Euro Heart Survey on atrial fibrillation / Eur. Heart J. 2005; 26(22): 2356–2357.
11. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patient who have nonvalvular atrial fibrillation / Ann. Intern. Med. 2007; 146: 857–867.
12. Connolly S.J., Eikelboom J., Joyner C. et al. For the AVERROES Steering Committee and Investigators. Apixaban in patients with Atrial Fibrillation / N. Engl. J. Med. 2011; 364: 806–817.
13. Connolly S.J., Ezekowitz M.D. et al. For the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation / N. Engl. J. Med. 2009; 361: 1139–1351.
14. Гиляров М.Ю., Магомадова М.У., Сулимов В.А. Алгоритм подборы дозы варфарина с учетом носительства полиморфизмов генов цитохрома CYP2C9 и субъединицы 1 витамин К эпоксиредуктазы / Вестник аритмологии. 2011; 63: 28–30. [Gilyarov M.Yu., Magomadova M.U., Sulimov V.A. Algorithm of selection of an optimal dose warfarin considering the polymorphism of cetochrome CYP2C9 gene and subunit 1 of vitamin k epoxide reductase gene / Vestar. 2011: 28–30] (In Russ).
Review
For citations:
Usenkov S.Yu., Batalov R.E., Borisova E.V., Khlynin M.S., Аrchakov E.A., Popov S.V. THE USE OF BLOOD COAGULATION LABORATORY PARAMETERS FOR ASSESSMENT OF BLEEDING RISK DURING RADIOFREQUENCY ABLATION PROCEDURE IN ATRIAL FIBRILLATION PATIENTS RECEIVING DABIGATRAN ETEXILATE. Siberian Journal of Clinical and Experimental Medicine. 2017;32(4):17-22. (In Russ.) https://doi.org/10.29001/2073-8552-2017-32-4-17-22
Views:
450
.png)
Email this article 